Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AgomAb Therapeutics NVAGMB · Entity 5259 | Director · Chief Executive Officer | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AgomAb Therapeutics NV
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common sharesSEC Table I · non-derivative | Direct | 21,823 |
Last balance in matching sequence
After 2026-10-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-05 · Purchase · Acquired 6,000 · Balance 16,823 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. Row 2 · 2026-10-06 · Purchase · Acquired 5,000 · Balance 21,823 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. |
| Common sharesSEC Table I · non-derivative | IndirectBy TJK Life Sciences B.V. | 34,394 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 34,394 F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. F2: Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
F2: Shares held by TJK Life Sciences B.V. ("TJK Life Sciences"). The Reporting Person exercises voting and dispositive power over the shares held by TJK Life Sciences and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 7, 2026 12:06 UTC | AgomAb Therapeutics NV AGMB · Entity 5259 | PurchaseCommon shares | 5,000 | $8.70 | $43,500.00 |
DisclosureSEC source: 0002120886-26-000001 · primary_doc.xml · nonDerivative · entry 2 Knotnerus Tim Jasper · CIK 0002120886 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,823 F1 · security: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 12:06 UTC | AgomAb Therapeutics NV AGMB · Entity 5259 | PurchaseCommon shares | 6,000 | $8.48 | $50,880.00 |
DisclosureSEC source: 0002120886-26-000001 · primary_doc.xml · nonDerivative · entry 1 Knotnerus Tim Jasper · CIK 0002120886 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,823 F1 · security: The common shares may be represented by American Depositary Shares, each of which currently represents one common share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.